MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the Canaccord Genuity 42nd Annual Growth Conference, set for August 8-11, 2022, in Boston, MA.

Rhea-AI Summary

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the Canaccord Genuity 42nd Annual Growth Conference, set for August 8-11, 2022, in Boston, MA. The management team will present on August 10 at 11:00 a.m. ET with an in-person format along with investor meetings. A live webcast will be accessible, and a replay will be available for 90 days on their website. MindMed is focused on developing innovative treatments for brain health disorders, targeting critical neurotransmitter systems.

Argus Session date unavailable

+4.23% session move Open Argus

Details

News Market Reaction – MNMD

The recorded move for MNMD in the trading session of this news was +4.23%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Aug. 2, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, to be held in Boston, MA, August 8-11, 2022.

Canaccord Genuity 42nd Annual Growth Conference
Format: In-person presentation and scheduled one-on-one investor meetings
Date: Wednesday, August 10, 2022
Time: 11:00 a.m. ET
Location: Boston, MA
Webcast Link: https://wsw.com/webcast/canaccord76/mnmd/2453508

A replay of the webcast will be available in the "News & Media" section of MindMed's website for 90 days following the presentation.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Media: media@mindmed.co

For Investors: ir@mindmed.co

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference-301597690.html

SOURCE Mind Medicine (MindMed) Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is MindMed participating in the Canaccord Genuity Growth Conference?

MindMed will participate in the Canaccord Genuity 42nd Annual Growth Conference from August 8-11, 2022.

What time is MindMed's presentation at the Canaccord Conference?

MindMed's presentation is scheduled for August 10, 2022, at 11:00 a.m. ET.

Where is the Canaccord Genuity Growth Conference being held?

The conference is being held in Boston, MA.

How can I access the webcast of MindMed's presentation?

The webcast can be accessed through a link provided in the press release, and a replay will be available for 90 days on MindMed's website.

What is MindMed's focus in drug development?

MindMed focuses on developing treatments for brain health disorders, particularly in psychiatry, addiction, pain, and neurology.